575 INTASYL self-delivering RNAi: A flexible platform to treat dermatological malignancies

INTASYL™ is a self-delivering RNAi technology platform that efficiently targets and silences specific mRNA in dermatological malignancies without needing additional delivery systems. It can target both intracellular and extracellular molecules and allows for the co-formulation of multiple compounds into a single therapeutic agent. Clinical investigations are underway for INTASYL PH-762 in treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma by silencing PD-1. INTASYL PH-894 targets the BET protein BRD4, showing cytotoxic effects on squamous cell carcinoma and enhancing melanoma immunogenicity. Other compounds targeting LAG3 and Cbl-b have shown in vitro efficacy, with LAG3 inhibitors enhancing immune response against melanoma and Cbl-b modulation potentially improving skin cancer treatment outcomes. The platform offers a promising and adaptable approach for treating skin cancers.